Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maartens

Showing results (51-60 of 582) with videos related to

Pageof 59
Sort By:
The Lancet. Infectious Diseases|April 17, 2015
Lower-dose efavirenz: what is needed before implementation?Gary Maartens, Graeme Meintjes
The Lancet. HIV|August 29, 2024
Where does doravirine fit in current antiretroviral therapy?Phumla Sinxadi, Gary Maartens
The Lancet. HIV|February 15, 2026
ART timing in people being investigated for tuberculosisGraeme Meintjes, Gary Maartens
The Lancet. Infectious Diseases|October 27, 2007
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?Ushma Mehta, Gary Maartens
The Lancet. Infectious Diseases|April 15, 2014
Dosing of raltegravir when given with rifampicinGraeme Meintjes, Gary Maartens
The Lancet. HIV|September 17, 2023
Dolutegravir dosing with rifampicin - Authors' replyGary Maartens, Rulan Griesel
Expert Opinion on Drug Safety|July 25, 2019
A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosisKaren Cohen, Gary Maartens
The Lancet. HIV|May 13, 2017
Resistance matters in EARNESTGary Maartens, Graeme Meintjes
Living Reviews in Relativity|July 11, 2017
Brane-World GravityRoy Maartens, Kazuya Koyama
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|June 1, 1994
Treatment of syphilis in HIV-infected individuals--more questions than answers?B Schon, G Maartens
Pageof 59

Showing results (51-60 of 582) with videos related to

Sort By:
Pageof 59
The Lancet. Infectious Diseases|April 17, 2015
Lower-dose efavirenz: what is needed before implementation?Gary Maartens, Graeme Meintjes
The Lancet. HIV|August 29, 2024
Where does doravirine fit in current antiretroviral therapy?Phumla Sinxadi, Gary Maartens
The Lancet. HIV|February 15, 2026
ART timing in people being investigated for tuberculosisGraeme Meintjes, Gary Maartens
The Lancet. Infectious Diseases|October 27, 2007
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?Ushma Mehta, Gary Maartens
The Lancet. Infectious Diseases|April 15, 2014
Dosing of raltegravir when given with rifampicinGraeme Meintjes, Gary Maartens
The Lancet. HIV|September 17, 2023
Dolutegravir dosing with rifampicin - Authors' replyGary Maartens, Rulan Griesel
Expert Opinion on Drug Safety|July 25, 2019
A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosisKaren Cohen, Gary Maartens
The Lancet. HIV|May 13, 2017
Resistance matters in EARNESTGary Maartens, Graeme Meintjes
Living Reviews in Relativity|July 11, 2017
Brane-World GravityRoy Maartens, Kazuya Koyama
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|June 1, 1994
Treatment of syphilis in HIV-infected individuals--more questions than answers?B Schon, G Maartens
Pageof 59